Cronos Group Inc. Common Share (CRON) — Analysis Summary
Cronos Group Inc. Common Share (CRON) has a market cap of $1.18B with year-over-year revenue growth of +24.6%. Net margin stands at -6.4%. The stock trades at a P/E ratio of 16.9.
Key Takeaways
- Revenue changed +24.6% year-over-year
- Net margin of -6.4%
- P/E ratio of 16.9
Compared to other companies in the MEDICINAL CHEMICALS & BOTANICAL PRODUCTS sector, CRON posted revenue growth of +24.6% and trades at a P/E of 16.9.
Cronos Group Inc. Common Share (CRON)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
Sector
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Employees
610
Headquarters
STAYNER, A6
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.